Previous 10 | Next 10 |
2024-01-08 11:47:12 ET More on Revance Therapeutics Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Public Citizen petitions FDA for stricter warnings against Botox, similar drug...
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 m...
2023-12-25 02:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...
2023-11-29 12:06:50 ET Summary Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of Daxxify - approved to treat frown lines, and recently a...
2023-11-14 17:52:57 ET More on Revance Therapeutics Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn Revance's FDA Nod: Beauty, Brains, And Balance Sheets Needham says Abbvie...
2023-11-08 22:50:20 ET Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Conference Call November 08, 2023, 04:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO ...
2023-11-08 16:23:27 ET Revance Therapeutics press release ( NASDAQ: RVNC ): Q3 GAAP EPS of -$1.63 misses by $0.69 . Revenue of $56.8M (+95.9% Y/Y) misses by $1.94M . Expects its 2023 GAAP operating expenses to be $545 million to $585 million. Cash, cash equ...
– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. – Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. – Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. – In Augus...
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales a...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday. Revance Therapeutics posted a GAAP loss of 54 cents per s...
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...